Perfusion Systems Market Share & Size | Industry Growth 2027

The Perfusion Systems market was valued at US$ 1,044.75 million in 2018, it is expected to grow at a CAGR of 3.8% from 2019 to 2027.

 

Perfusion is the passage of fluid through the circulatory system or lymphatic system to an organ or a tissue, usually referring to the delivery of blood to a capillary bed in tissue. Perfusion is measured as the rate at which blood is delivered to tissue, or volume of blood per unit time (blood flow) per unit tissue mass. During major surgery, perfusion must be maintained and managed by the health professionals involved, rather than left to the body's homeostasis alone. The growth of the Perfusion Systems market is attributed to the rising prevalence of cardiovascular diseases, significant growth of pharmaceutical and biotechnology industries, rising need for the organ transplantation and rising cell based research activities play vital role in the growth of the perfusion systems market. However, the challenges such as expensive organ transplant surgeries and limited numbers of donors for organ transplant surgeries are likely to impact the growth of the market in the forecast period. On the other hand, technological development from emerging nations hold a significant opportunity for the market growth in the coming years.

The Perfusion Systems market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Market Insights

Growing Applications of Perfusion Systems in Healthcare to Drive Perfusion Systems Market Growth

Cardiovascular diseases (CVDs) are the disorders of the heart and blood vessels and include cerebrovascular disease, coronary heart disease, rheumatic heart disease and other conditions. Some of the major factors which leads to the death and difficulties are use of tobacco, unhealthy diet, and physical inactivity which increases the risk of heart attacks and strokes. CVDs are the leading cause of death across the globe, it affects more people as compared to any other disease. Other than the lifestyle and habit older people are more prone to the cardiovascular diseases. The ageing population commonly show the structural and functional alteration of vessels accumulation through their life. Thus it increases the risk of developing cardiovascular diseases. 

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Perfusion Systems Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

The prevalence of the cardiovascular diseases is increasing across the world. The key factors that lead to the occurrence of cardiovascular diseases among the population. Cardiovascular diseases are major cause of the deaths across the world. As per the American College of Cardiology, it is stated that CVD contributes nearly 800,000deaths in the US, which is approximately to one out every three deaths. The coronary heart disease (CHD) contributes to the majority of CVD deaths which is further followed by stroke and heart failure. Nearly over 90 million Americans get diagnosed with CVD. In addition, it is stated that at a global level cardiovascular diseases contributes around 31% of all deaths and is expected that the cost of the CVD will be approximately to US$ 1,044 billion by 2030.

In Europe, every year cardiovascular disease (CVD) causes 3.9 million deaths and more than 1.8 million deaths in the European Union (EU). The CVD accounts for 45.0% of all deaths in Europe and 37.0% of all deaths in the EU. CVD is the major reason of the death in men and women in all countries. Therefore, the perfusion systems are required to bypasses the function of the heart and lung during the heart surgery and helps in maintaining the circulation of blood and the oxygen content of the body. Hence, owing to the rising prevalence of cardiovascular diseases in the regions and in various countries, the need of perfusion systems for the treatment of the CVD are likely to increases the market during the forecast period.

The perfusion systems market is also driven by the significant growth of pharmaceutical and biotechnology industry. In the past few years, pharmaceutical and biotechnological industry has been developing at an unusually rapid pace. The rise in the prevalence of the chronic and acute diseases are alarming the need of the medicines, therapeutic, vaccines, antibiotics and others. The technological advancements have assisted the manufacturers with ease in technique to enhance their production. These manufacturers along with their alliance with the contract research organizations (CROs) are confronting to the enormous healthcare challenges through new medicines, therapy forms, progressing digitalization and constantly changing the regulations. In addition, the rise in the geriatric population is leading to rising healthcare conditions. As per the World Health Organization, the global population is increasing by 1.24% per annum leading to rise in number of people in the geriatric class. 

The WHO also suggests that the proportion of people aged 65 to 80 will rise to 28% in 2030, compared to 22% in 2000. Moreover, according to a survey report published by Torreya Economical Model 2017, pharmaceutical industry is 30% larger than its previous estimations till 2017 and contributes to one of the top five industries increasing global economy value.

Furthermore, the increase in the start-up companies for the pharmaceutical, biopharmaceutical and biotechnology are growing with a good number across the world. These companies are developing innovative drug and therapeutic products and been supported by the respective governments of the countries. Therefore, enormous growth in the production of the medicine and other therapeutic products is shown by the start-up and established players. The production of the medicines and therapeutic products requires the perfusion systems and perfusion systems to produce the raw materials obtained by the biological source. The biotechnology companies are also engaged in the production of the raw materials for the agriculture, food and beverage and other sectors. In contrast to the pharmaceutical industry, biotechnology companies require perfusion systems more. Hence, owing to these factors the market for the perfusion systems is likely to propel in the coming forecast years.

Organ transplantation is a surgical process done when a patient’s organ has stopped functioning completely. The organ transplant is commonly done for the organs such as heart, liver and kidney. However, the rising cases of the chronic diseases are leading to the need of the transplantation for the other organs such as lung, pancreases, cornea, and vascular tissues among others. Organ transplantation is considered as one of the great advanced in the modern medical industry. 

The rise in the chronic diseases that causes damages the functions heart, lung, liver, kidney and other organs are leading to the increasing number of the organ transplantation. The organ transplantation surgeries are rising across the world. For instance, in Spain, approximately 5,260 transplant surgeries were performed, among which nearly 3,200 were kidney transplant and around 1,200 were liver transplant surgeries. The number of heart transplant surgeries were approximately 300 and lung were nearly 360. The public-private partnership in assistance with the transplant coordinators has enormously contributed to the improvement of the organ transplantation. The developing and developed countries have shown good numbers of the organ transplantation surgeries. For instance, developing countries like India and Singapore are emerging as medical tourism destination in the Asia Pacific region. The countries are growing in terms of offering better and advanced medical treatments. 

As per the National Chronic Kidney Disease fact sheet 2017, states that approximately, 30 million people in US are estimated to have chronic kidney diseases. Similarly, according to the National Institute id Diabetes and Digestive and Kidney Diseases states that nearly 661,000 Americans have kidney failure among these nearly, 468,000 patients are taking dialysis, and approximately 193,000 have undergone kidney transplantation. Therefore, the increasing incidences are likely to grow more needs for the kidney transplantation in the coming years. Likewise, it is estimated that the growing numbers of the heart diseases are also responsible to drive the market in coming futures. Thus, the rising need for the organ transplantation is among the key driving factors for the perfusion systems market.

The rise in the chronic diseases, advantages of the applications of biotechnology are growing the extensive cell based research activities. The cell based assays assists in understanding the challenges of biology of the living organisms. The study and research helps to understand the disease processes and its complexity. The cell based assays helps in the understanding the aspects such as cell signaling, proliferation, apoptosis, cellular genetics, neurology, cancer and more. 

The cell based assays are extensively carried out in pharmaceutical, biotechnology industries, research institutes and academics research institutes. The pharmaceutical and biopharmaceutical industries need to efficiently commercialize the drug. Therefore, cell based assays in the pharmaceutical and biotechnology industry are the driving factor for the growth of the perfusion systems. 

The cell based assays are also extensively carried out by the contract research organization for the clinical trial studies and other processes. The chronic diseases such as cancer and other genetic related studies are enforcing for the cell based studies. For instance, Charles River offers services for the human primary cell based assays and according to an article published by the company states that the development in the cell based assays are likely to continue growing in the future. It states that the cell based assays are helpful in the drug discovery as the in vitro to in vivo correlation plays a vital role in the development of a drug. Thus, the increasing cell based research activities are likely to drive the perfusion systems in the forecast period.

Type-Based Insights

In terms of type, the Perfusion Systems market is segmented into microfluidic perfusion systems, small-mammal organ perfusion systems, bioreactor perfusion systems, gravity or pressure-driven perfusion systems. In 2018, the bioreactors perfusion systems segment held a largest market share of 44.3% of the perfusion systems market, by type.

Component-Based Insights

Based on component, the Perfusion Systems in market is segmented into perfusion pumps, oxygenators, heart-lung machines, monitoring systems, cannulas, others. Oxygenators segment is anticipated to grow at a CAGR of 4.4% during the forecast period.

The Perfusion Systems market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

Perfusion Systems Market Regional Insights

The regional trends and factors influencing the Perfusion Systems Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Perfusion Systems Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Perfusion Systems Market Report Scope

Perfusion Systems Market Players Density: Understanding Its Impact on Business Dynamics

The Perfusion Systems Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Perfusion Systems Market are:

1. REPLIGEN CORPORATION
2. Merck KGaA
3. Ala Scientific Instruments, Inc.
4. XVIVO Perfusion
5. Medtronic

Disclaimer: The companies listed above are not ranked in any particular order.

 

Perfusion Systems Market – by Type

• Microfluidic Perfusion Systems
• Small-Mammal Organ Perfusion Systems
• Bioreactor Perfusion Systems
• Gravity or Pressure-Driven Perfusion Systems

Perfusion Systems Market – by Component

• Perfusion Pumps
• Oxygenators
• Heart-Lung Machines
• Monitoring Systems
• Cannulas
• Others

Perfusion Systems Market – by Geography

• North America

  • US
  • Canada
  • Mexico

• Europe

  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe

• Asia Pacific (APAC)

  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of APAC

• Middle East & Africa (MEA)

  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

• South America and Central America (SCAM)

  • Brazil
  • Argentina
  • Rest of SCAM

 

Company Profiles

• REPLIGEN CORPORATION
• Merck KGaA
• Ala Scientific Instruments, Inc.
• XVIVO Perfusion
• Medtronic
• XENIOS AG (Fresenius Medical Care AG & Co. KGaA)
• Getinge AB
• TERUMO CORPORATION
• LivaNova PLC
• Sartorius AG
• Harvard Bioscience
• RAND
• Sanisure (Sani-Tech West, Inc.)
• AutoMate Scientific, Inc
• Jobst Technologies GmbH
• APD (Advanced Perfusion Diagnostics)
• Spectrum Medical, Transonic Systems Inc
• OrganOx
• ISCHEMAVIEW, INC
• CESCO BIOENGINEERING CO., LTD